Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivenprost in mild to moderate ulcerative colitis
NCT00296556Phase 2Terminated
- Sponsor
- Kyoto University
- Start
- Feb 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing Rivenprost with Placebo (2 arms). Primary endpoint: Remission evaluated by DAI scores at 28 days. Started Feb 2006; status: terminated.
02
Drugs
rivenprost
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00296556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00296556.